Dean L. Schorno
2019 - Rigel Pharmaceuticals
In 2019, Dean L. Schorno earned a total compensation of $1M as Executive Vice President and Chief Financial Officer at Rigel Pharmaceuticals, a 13% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $191,580 |
|---|---|
| Option Awards | $420,682 |
| Salary | $412,000 |
| Other | $8,954 |
| Total | $1,033,216 |
Schorno received $420.7K in option awards, accounting for 41% of the total pay in 2019.
Schorno also received $191.6K in non-equity incentive plan, $412K in salary and $9K in other compensation.
Rankings
In 2019, Dean L. Schorno's compensation ranked 9,140th out of 13,971 executives tracked by ExecPay. In other words, Schorno earned more than 34.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 9,140 out of 13,971 | 35th |
Division Manufacturing | 3,665 out of 5,701 | 36th |
Major group Chemicals And Allied Products | 1,387 out of 2,200 | 37th |
Industry group Drugs | 1,184 out of 1,886 | 37th |
Industry Pharmaceutical Preparations | 878 out of 1,398 | 37th |
Source: SEC filing on April 1, 2020.
Schorno's colleagues
We found six more compensation records of executives who worked with Dean L. Schorno at Rigel Pharmaceuticals in 2019.
2019
Raul Rodriguez
Rigel Pharmaceuticals
Chief Executive Officer
2019
Anne-Marie Duliege
Rigel Pharmaceuticals
Chief Medical Officer
2019
Dolly Vance
Rigel Pharmaceuticals
Executive Vice President, Corporate Affairs, General
2019
Eldon Mayer
Rigel Pharmaceuticals
Executive Vice President, Chief Commercial Officer
2019
Esteban Masuda
Rigel Pharmaceuticals
Executive Vice President, Research
2019
Wolfgang Dummer
Rigel Pharmaceuticals